Inhibition of hepatitis-B-virus core promoter by p53: Implications for carcinogenesis in hepatocytes

International Journal of Cancer

Volumn 67, Issue 6, 1996, Pages 892-897

  Uchida, Takafumi ^a   Takahashi, Katsuhiko ^a   Tatsuno, Kenji ^a   Dhingra, Urvashi ^b   Eliason, James F ^a,c  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

^b HOFFMANN LA ROCHE INC   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; GENES, REPORTER; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; LUCIFERASES; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRAL CORE PROTEINS;

EID: 0029861156     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960917)67:6<892::AID-IJC21>3.0.CO;2-2     Document Type: Article

References (30)

1. AGUILAR, F., HARRIS, C.C., SUN, T., HOLLSTEIN, M. and CERUTTI, P., Geographic variation of p53 mutational profile in non-malignant human liver. Science, 264, 1317-1319 (1994).
2. AGUILAR, F., HUSSAIN, S.P. and CERUTTI, P., Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor-suppressor gene in human hepatocytes. Proc. nat. Acad. Sci. (Wash.), 90, 8586-8590 (1993).
3. BEASLEY, R.P., HWANG, L.-Y., LIN, C.-C. and CHIEN, C.-S., Hepatocellular carcinoma and hepatitis-B virus. A prospective study or 22,707 men in Taiwan. Lancett, II, 1129-1133 (1981).
4. BRESSAC, B., KEW, M., WANDS, J. and OZTURK, M., Selective G-to-T mutations of p53 gene in hepalocellular carcinoma from southern Africa. Nature (Lond.), 350, 429-431 (1991).
5. BUETOW, K.H., SHEFFIELD, V.C., ZHU, M., ZHOU, T., SHEN, F.-M., HINO, O., SMITH, M., MCMAHON, B.J., LANIER, A.P., LONDON, W.T., REDEKER, A.G. and GOVINDARAJAN, S., Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. nat. Acad. Sci. (Wash.), 89, 9622-9626 (1992).
6. DIAMANTIS, I.D., MCGANDY, C.E., CHEN, T.-J., LIAW, Y.-F., GUDAT, F. and BIANCHI, L., Hepatitis-B X-gene expression in hepatocellular carcinoma. J. Hepatol., 15, 400-403 (1992).
7. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
8. FEITELSON, M.A., ZHU, M., DUAN, L.-X. and LONDON, W.T., Hepatitus-B × antigens are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8, 1109-1117 (1993).
9. GANEM, D. and VARMUS, H.E., The molecular biology of the hepatitis-B viruses. Ann. Rev. Biochem., 56, 651-693 (1987).
10. HOLLSTEIN, M.C., WILD, C.P., BLEICHER, F., CHUTIMATAEWIN, S., HARRIS, C.C., SRIVATANAKUL, P. and MONTESANO, R., p53 mutations and aflatoxin-B1 exposure in hepatocellular-carcinoma patients from Thailand. Int. J. Cancer, 53, 51-55 (1993).
11. HSU, I.C., METCALF, R.A., SUN, T., WELSH, J.A., WANG, N.J. and HARRIS, C.C., Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond.), 350, 427-428 (1991).
12. HSU, I.C., TOKIWA, T., BENNETT, W., METCALF, R.A., WELSH, J.A., SUN, T. and HARRIS, C.C., p53 gene mutation and integrated hepatitis-B viral DNA sequences in human liver-cancer cell lines. Carcinogenesis, 14, 987-992 (1993).
13. JWO, S.-C., CHIU, J.-H., CHAU, G.-Y., LOONG, C.C. and LUI, W.-Y., Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology, 16, 1367-1371 (1992).
14. KEKULÉ, A.S., LAUER, U., WEISS, L., LUBER, B. and HOFSCHNEIDER, P.M., Hepatitis-B-virus transactivator HBX uses a tumour-promoter-signalling pathway. Nature (Lond.), 361, 742-745 (1993).
15. KIM, C.-M., KOIKE, K., SAITO, I., MIZAMURA, T. and JAY, G., HBX gene of hepatitis-B virus induces liver cancer in transgenic mice. Nature (Lond.), 351, 317-320 (1991).
16. OKAYAMA, H., KAWAICHI, M., BROWNSTEIN, M., LEE, F., YOKOTA, T. and ARAI, K., Efficient cloning of full-length cDNA. Methods Enzymol., 154, 3-28 (1987).
17. ROSSNER, M.T., JACKSON, R.J. and MURRAY, K., Modulation of expression of the hepatitis-B-virus surface antigen gene by the viral X-gene product. Proc. roy. Soc. London, 241, 51-58 (1990).
18. SCHRODER, C.H, and ZENTGRAF, H., Hepatitis-B-virus-related hepatocellular carcinoma: chronicity of infection - the opening to different Pathways of malignant transformation? Biochim. biophys. Acta, 1032, 37-156 (1990).
19. SCORSONE, K.A., ZHOU, Y.-Z., BUTEL, J.S. and SLAGLE, B.L., p53 mutations cluster at codon 249 in hepatitis-B-virus-positive hepatocellular carcinomas from China. Cancer Res., 52, 1535-1638 (1992).
20. SHEKHAR, P.V.M., CHRISTMAN, J.K., JONES, R.F. and WERDELL, J., Altered p53 conformation in neoplastic progression of MCF10AneoT xenograft model. Proc. Amer. Ass. Cancer Res., (1996). (In press).
21. SHEN, J.-C., HUANG, G.-T., LEE, P.-H., CHUNG, J.-C., CHOU, H.-C., LAI, M.-Y., WANG, J.-T., LEE, H.-S., SHIH, L.-N., YANG, P.-M., WANG, T.-H. and CHEN, D.-S., Mutation of p53 gene in hepatocellular carcinoma in Taiwan, Cancer Res., 52, 6098-6100 (1992).
22. SHIMODA, R., NAGASHIMA, M., SAKAMOTO, M., YAMAGUCHI, N., HIROHASHI, S., YOKOTA, J. and KASAI, H., Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res., 54, 3171-3172 (1994).
23. SLAGLE, B.L., LE, T.-H. and BUTEL, J.S., Hepatitis-B virus and hepatocellular carcinoma. Prog. med. Virol., 39, 167-203 (1992).
24. SOUSSI, T., LEGROS, Y., LUBIN, R., ORY, K. and SCHLICHTHOLZ, B., Multifactorial analysis of p53 alteration in human cancer - a review. Int. J. Cancer, 57, 1-9 (1994).
25. SPANDAU, D.F, and LEE, C., Trans-activation of viral enhancers by the hepatitis-B-virus X protein. J. Virol., 62, 427-434 (1988).
26. TAKEMURA, F., ISHII, T., FUJII, N. and UCHIDA, T., Complete nucleotide sequence of hepatitus-B virus. Nucleic Acids Res., 18, 4587 (1990).
27. TERAMOTO, T., SATONAKA, K., KITAZAWA, S., FUJIMORI, T., HAYASHI, K. and MAEDA, S., p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis, Cancer Res., 54, 231-235 (1994).
28. WAGA, S., HANNON, G.J., BEACH, D. and STILLMAN, B., The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369, 574-578 (1994).
29. WANG, X.W., FORRESTER, K., YEH, H., FEITELSON, M.A., GU, J.-R. and HARRIS, C.C., Hepatitis-B-virus × protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. nat. Acad. Sci. (Wash.), 91, 2230-2234 (1994).
30. ZHU, Y.-M., BRADBURY, D.A. and RUSSELL., N.H., Wild-type p53 is required for apoptosis induced by growth-factor deprivation in factor-dependent leukaemic cells. Brit. J. Cancer, 69, 468-472 (1994).